EMA Withdrawn: Glubrava (metformin hydrochloride;pioglitazone hydrochloride) — Takeda Pharma A/S

View source ↗

Summary

Glubrava, a fixed-dose combination of metformin hydrochloride and pioglitazone hydrochloride, has been withdrawn from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Glubrava
• metformin hydrochloride;pioglitone hydrochloride

Snippet

Status: Withdrawn. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Takeda Pharma A/S. Decision date: 04/02/2021